MDCM
CCCC icon

Morgan Dempsey Capital Management’s C4 Therapeutics CCCC Stock Holding History

Morgan Dempsey Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,500
Closed -$8.55K – 129
2024
Q3 		$8.55K Buy
+1,500
New +$9.03K ﹤0.01% 113

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Dempsey Capital Management's CCCC Position: Q4 2024 in Review

Morgan Dempsey Capital Management sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 1,500 shares — an estimated $8.55K sold.

Morgan Dempsey Capital Management first reported a position in CCCC in Q3 2024 and held it in 1 quarter. The position peaked at $8.55K in Q3 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Morgan Dempsey Capital Management reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Morgan Dempsey Capital Management sold 1,500 C4 Therapeutics shares in Q4 2024, an estimated $8.55K.
  • Morgan Dempsey Capital Management first reported a position in C4 Therapeutics in Q3 2024 and held it in 1 quarter.
  • Morgan Dempsey Capital Management's C4 Therapeutics position peaked at $8.55K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Morgan Dempsey Capital Management's 13F filing for Q4 2024, filed 5 Feb 2025.